Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,912.00
+441.00 (29.98%)
Feb 5, 2026, 3:30 PM KST
Xcell Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 |
Depreciation & Amortization | 1,710 | 1,653 | 1,598 | 1,513 | 1,019 | 681.79 |
Loss (Gain) From Sale of Assets | -85.09 | 130.13 | -21 | 0.53 | 12 | -3 |
Asset Writedown & Restructuring Costs | - | - | 154.12 | - | - | - |
Loss (Gain) From Sale of Investments | -9.43 | -2.72 | 0.87 | - | - | - |
Stock-Based Compensation | 206.27 | 228.31 | 283.67 | 540.12 | 354.46 | 74.09 |
Provision & Write-off of Bad Debts | 339.31 | 259.89 | 50 | - | - | - |
Other Operating Activities | 458.87 | 383.97 | 587.39 | 230.17 | 3,453 | 5,789 |
Change in Accounts Receivable | 59.45 | -31.37 | -301.81 | -104.98 | -133.14 | -16.93 |
Change in Inventory | -831.8 | 60.58 | -178.38 | -186.23 | 179.52 | -37.8 |
Change in Accounts Payable | 67.43 | 46.38 | 43.66 | -137.29 | -239.85 | -82.44 |
Change in Other Net Operating Assets | -276.91 | -180.91 | 280.29 | -808.69 | -211.69 | -258.36 |
Operating Cash Flow | -8,371 | -6,996 | -6,784 | -7,296 | -4,605 | -3,978 |
Capital Expenditures | -902.07 | -382.69 | -224.82 | -1,179 | -1,347 | -1,679 |
Sale of Property, Plant & Equipment | 110 | - | 55 | - | 0.45 | 3 |
Sale (Purchase) of Intangibles | -684.93 | -437.34 | -8.83 | -145.48 | -49.14 | -17.36 |
Investment in Securities | -1,171 | -1,780 | -3.96 | -131.88 | -3.88 | 14.07 |
Other Investing Activities | -46.57 | 1,328 | 4.06 | -10 | -259.51 | 132.67 |
Investing Cash Flow | -2,694 | -1,272 | -178.55 | -1,466 | -1,659 | -1,546 |
Long-Term Debt Issued | - | 1,950 | 350 | - | 3,000 | 2,270 |
Long-Term Debt Repaid | - | -3,035 | -587.44 | -455.54 | -759.28 | -1,587 |
Net Debt Issued (Repaid) | 38.97 | -1,085 | -237.44 | -455.54 | 2,241 | 683.45 |
Issuance of Common Stock | 49.84 | 15,875 | 3,000 | 16.66 | 8,092 | 6,000 |
Other Financing Activities | -3.2 | -0 | - | - | - | - |
Financing Cash Flow | 85.61 | 14,790 | 2,763 | -438.88 | 14,232 | 11,384 |
Foreign Exchange Rate Adjustments | 1,237 | 1,239 | 2.2 | 4.66 | 2.15 | - |
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | 0 |
Net Cash Flow | -9,743 | 7,761 | -4,197 | -9,196 | 7,971 | 5,859 |
Free Cash Flow | -9,273 | -7,379 | -7,008 | -8,475 | -5,952 | -5,657 |
Free Cash Flow Margin | -680.78% | -381.48% | -623.58% | -830.82% | -302.69% | -1047.18% |
Free Cash Flow Per Share | -847.76 | -737.48 | -792.48 | -968.02 | -718.67 | -3175.38 |
Cash Interest Paid | 290.91 | 343.69 | 284.27 | 209.73 | 104.88 | 78.33 |
Cash Income Tax Paid | - | 23.06 | -8.31 | 11.26 | 3.73 | - |
Levered Free Cash Flow | -6,965 | -5,076 | -3,926 | -5,606 | -6,886 | -1,445 |
Unlevered Free Cash Flow | -6,965 | -5,074 | -3,924 | -5,604 | -6,774 | -927.88 |
Change in Working Capital | -981.83 | -105.33 | -156.23 | -1,237 | -405.17 | -395.53 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.